#None #Boston #Pulmonary Hypertension #Synhale Therapeutics #Telaglenastat

Synhale Therapeutics Accelerates Pulmonary Hypertension Treatment

On May 1, 2025, Synhale Therapeutics Inc., a pioneering virtual biotech firm, announced a significant advancement in its mission to treat Pulmonary Hypertension (PH) with the acquisition of Telaglenastat (CB-839), a first-in-class glutaminase inhibitor. This strategic move is set to accelerate Synhale's clinical programs across all four groups of PH, addressing a critical area in the medical field where treatment options are still lacking.

A Transformational Step for Synhale

Chad D. Holland, the President and CEO of Synhale, emphasized the importance of this acquisition by stating, "This acquisition represents a unique opportunity to rapidly deliver clinical data addressing a disease with high mortality and substantial market potential.” With past clinical experiences and promising research, Synhale aims to transition Telaglenastat into a Phase 2 clinical program, thereby enhancing patient access to potentially life-saving therapies.

PH is a severe condition that complicates and intensifies with other existing health problems, leading to a significantly increased risk of mortality. Notably, Groups 2 and 3 of PH are marked by heart failure with preserved ejection fraction (HFpEF) and chronic lung diseases like Chronic Obstructive Pulmonary Disease (COPD), both presenting dire outcomes for patients. According to Stephen Chan, MD, PhD and Founder of Synhale, the mortality rate for patients with PH and HFpEF can approach 50% within five years, highlighting the urgent need for effective treatment solutions.

Targeting the Root Causes of PH

Synhale's approach revolves around addressing elevated glutaminase activity, which is a central driver behind the vascular, cardiac, and pulmonary complications associated with PH. This acquisition opens a pathway not only for rare forms of PH, such as Pulmonary Arterial Hypertension (Group 1), but also for more common forms related to heart failure and lung diseases.

Telaglenastat has already been previously dosed in over 800 patients during the development process for oncology, positioning it as a promising candidate ready to take on the challenges posed by PH, backed by significant preclinical data. With an estimated market opportunity between $12 billion and $24 billion across all four PH groups, Synhale's strategic focus on Telaglenastat could place them at the forefront of PH treatment innovations.

Future Directions for Synhale

In light of these developments, Holland stated that Synhale is embarking on a new fundraising round to navigate the Telaglenastat program through critical clinical milestones. Their virtual operating model aims to be capital-efficient while enabling them to attract world-class expertise to foster breakthroughs in the treatment of PH.

Conclusion

As Synhale Therapeutics takes this bold step forward in acquiring Telaglenastat, stakeholders are hopeful about the future of pulmonary hypertension therapies. The commitment to address the unmet needs within this patient population signifies a transformative moment not just for the company, but also for patients suffering from this life-threatening condition. Synhale's mission to redefine PH treatment through science-driven solutions points towards a future where effective management and potential cures are more accessible than ever.